Adjuvant treatment in patients with melanoma
| Autor: | Carin A. Uyl-de Groot, Stefan Sleijfer, Dirk J. Grünhagen, Evalyn E. A. P. Mulder, Astrid A M van der Veldt |
|---|---|
| Přispěvatelé: | Surgery, Medical Oncology, Health Technology Assessment (HTA), Radiology & Nuclear Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Skin Neoplasms Time Factors medicine.medical_treatment MEDLINE Aftercare Disease-Free Survival Patient Care Planning SDG 3 - Good Health and Well-being Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans In patient Melanoma Neoplasm Staging business.industry medicine.disease Progression-Free Survival Chemotherapy Adjuvant Practice Guidelines as Topic Neoplasm Recurrence Local Tomography X-Ray Computed business Adjuvant |
| Zdroj: | European Journal of Cancer, 157, 306-307. Elsevier Ltd. |
| ISSN: | 1879-0852 0959-8049 |
| Popis: | As an increasing number of patients with melanoma is being treated with adjuvant systemic therapy, there is a growing need for an effective and efficient follow-up strategy to address issues such as radiation burden, increasing costs, and limited resources and scanning capacity. In addition, early detection of recurrent disease is crucial to determine the treatment plan while aiming to prevent unnecessary exposure to subsequent treatments with all accompanying costs, toxicities and fear for patients. So far, no consensus has been reached on the follow-up scheme in patients with melanoma treated with adjuvant therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect